1.5 Abstract su Rivista

1.5 Abstract su Rivista: [1217] Home page tipologia

Sfoglia

Prodotti della tipologia (ordinati per Data di deposito in Decrescente ordine): 721 a 740 di 1.217

Growth inhibition of tumor cells by epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is associated with upregulation of p27 and p21 cyclin-dependent kinase inhibitors.

1999 E., Di Gennaro; M., Barbarino; F., Bruzzese; S., De Lorenzo; Pepe, Stefano; F., Caponigro; A., Budillon

EGF-R tyrosyne kinase as new target in melanoma treatment; Synergistic effect of IFN alpha in combination with ZD1839 )Iressa) , an EGFR tyrosine kinase inhibitor.

2001 E., Di Gennaro; F., Bruzzese; A., Avallone; G., Pirozzi; Pepe, Stefano; G., Comella; F., Caponigro; A., Budillon

MEK-1 inhibitor PDO8059 potentiates apoptosis and growth inhibition induced by intereferon alpha (IFN alpha) in human epidermoid cancer cells.

2000 M., Caraglia; P., Tagliaferri; P., Tassone; G., Giuberti; M., Marra; Pepe, Stefano; A., Budillon; E., Di Gennaro; A. R., Bianco; A., Abbruzzese; S., Venuta

Growth arrest, apoptosis and potentiation of 5-fluorouracil and Raltitrexed cytotoxic effect induced by histone deacetylase inhibitor SAHA in colorectal cancer cells.

2002 A., Budillon; E., Di Gennaro; Pepe, Stefano; F., Bruzzese; G., Romano; I., Pelagianis; P., Mascagni; F., Leoni

A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FLFOX-4) as first-line treatment of advanced gastric cancer patients.

2004 F., De Vita; M., Orditura; E., Matano; R., Bianco; C., Carlomagno; S., Infusino; V., Damiano; E., Simeone; M. R., Diadema; E., Lieto; P., Castellano; Pepe, Stefano; S., De Placido; G., Galizia; F., Ciardiello; G., Catalano; A. R., Bianco

A phase I-II trial of gefitinib (IRESSA) and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck (SCCHN)

2005 F., Caponigro; G., Franchin; V., Rav; G., Silvestro; B., Morrica; C., Romano; E., Minatel; Pepe, Stefano

The farnesyltransferase inhibitor R115777 (Zanestra) synergizes with ionizing radiation in inducing cell cycle perturbation and growth inhibition of human epidermoid head and neck cancer cells.

2006 Pepe, Stefano; Pacelli, R.; Chianese, M.; Budillon, A.; Abbruzzese, A.; Marra, M.; Sabbatino, F.; Laus, G.; Caraglia, M.

Potentiation of the antitumor acitivity of bortezomib, a proteasome inhibitor, by the combination with EGFR inhibitors in human cancer cell lines.

2006 T., Cascone; F., Morgillo; G., Laus; Pepe, Stefano; F., Ciardiello

Synergistic antitumor activity of the combination of the multi-targetes tyrosine kinase inhibitor sorafenib and of EGFR inhibitors in human colon and lung cancer cell lines.

2006 E., Martinell; T., Troiani; G., Laus; Pepe, Stefano; F., Ciardiello

Phase I-II study of xelox and bevacizumab plus erlotinib in sequential combination (XELO-TARAV) in first line colorectal cancer: Run in part.

2007 G., Tortora; C., Carlomagno; R., Bianco; G., Daniele; Pepe, Stefano; D., Leopardo; R., Marciano; M., De Laurentiis; F., Ciardiello; S., De Placido

Inhibition of poly(ADP-Ribose)plymerase synergizes with the DNA-topoisomerase-1-inhibitor, topoteca, and radiation in human glioblastoma cell lines.

2008 Sabbatino, F.; Pacelli, R.; Punzo, G.; Fusciello, C.; Vernieri, C.; Della Vittoria Scarpati, G.; Pepe, Stefano

Cell growth-inhibition and cell cycle perturbations induced by a new synthetic iminoquinone, 5H-pyridophenoxazin-5-one, in human breast carcinoma cell lines.

2007 Fusciello, C.; Bolognose, A.; La Vecchia, A.; Ubezio, P.; Sabbatino, F.; Pepe, Stefano

Predictive factors of response to neoadjuvant chemoradiotherapy in rectal cancer patirnts.

2008 C., Carlomagno; F., D'Armiento; A., Crispo; G., Della Vittoria Scarpati; M., D'Armiento; M., Marra; L., Cannella; A., De Stefano; M., Colantuoni; S., Alfieri; S., De Placido; Pepe, Stefano

Phase I-II study of sequential combination of XELOX and bevacizumab plus erlotinib (XELOX-TARAV) in first line colorectal patients:Run in phase I part

2008 C., Carlomagno; R., Bianco; G., Daniele; R., Marciano; Pepe, Stefano; V., Adamo; F., Ciardiello; S., De Placido; G., Tortora

Autoimmune manifestations in children transplanted for non-autoimmune liver diseases

2001 Clemente, Mg; Vajro, Pietro; Musu, Mp; Cicotto, L; Ciccimarra, E; Mandato, Claudia; De Virgiliis, S.

REDUCED LEVELS OF SHP1 PROVIDES AN ADDITIVE SURVIVAL ADVANTAGE TO THE PH(+) CELLS OF CML PATIENTS AND MAY ACCOUNT FOR RESISTANCE TO IMA TREATMENT

2008 N., Esposito; I., Colavita; B., Izzo; F., Quarantelli; R. A., Sica; T., Buonomo; V., Roberti; L., Luciano; L. D., Vecchio; A., Peluso; J. V., Melo; D., Russo; G., Martinelli; Martinelli, Rosanna; M., Ruoppolo; F., Pane

Multiple molecular mechanism may account for resistance to imatinib in resistant cell lines

2007 N., Esposito; B., Izzo; F., Quarantelli; I., Colavita; T., Buonomo; V., Roberti; S., Soverini; J. V., Melo; G., Martinelli; Martinelli, Rosanna; M., Ruoppolo; B., Rotoli; F., Pane

THE REGULATION OF TRANSCRIPTION DURING THE CELL-CYCLE

1993 N., Heintz; F., Labella; Martinelli, Rosanna; N., Segil

H1TF2A - A NOVEL HUMAN TRANSCRIPTION FACTOR INVOLVED IN HISTONE H1 CELL-CYCLE REGULATION

1994 Martinelli, Rosanna; N., Heintz

HISTONE GENE-TRANSCRIPTION DURING THE CELL-CYCLE

1994 F., Labella; Martinelli, Rosanna; N., Segil; N., Heintz

Titolo	Data di pubblicazione	Autore(i)
Growth inhibition of tumor cells by epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is associated with upregulation of p27 and p21 cyclin-dependent kinase inhibitors.	1-gen-1999	E., Di Gennaro; M., Barbarino; F., Bruzzese; S., De Lorenzo; Pepe, Stefano; F., Caponigro; A., Budillon
EGF-R tyrosyne kinase as new target in melanoma treatment; Synergistic effect of IFN alpha in combination with ZD1839 )Iressa) , an EGFR tyrosine kinase inhibitor.	1-gen-2001	E., Di Gennaro; F., Bruzzese; A., Avallone; G., Pirozzi; Pepe, Stefano; G., Comella; F., Caponigro; A., Budillon
MEK-1 inhibitor PDO8059 potentiates apoptosis and growth inhibition induced by intereferon alpha (IFN alpha) in human epidermoid cancer cells.	1-gen-2000	M., Caraglia; P., Tagliaferri; P., Tassone; G., Giuberti; M., Marra; Pepe, Stefano; A., Budillon; E., Di Gennaro; A. R., Bianco; A., Abbruzzese; S., Venuta
Growth arrest, apoptosis and potentiation of 5-fluorouracil and Raltitrexed cytotoxic effect induced by histone deacetylase inhibitor SAHA in colorectal cancer cells.	1-gen-2002	A., Budillon; E., Di Gennaro; Pepe, Stefano; F., Bruzzese; G., Romano; I., Pelagianis; P., Mascagni; F., Leoni
A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FLFOX-4) as first-line treatment of advanced gastric cancer patients.	1-gen-2004	F., De Vita; M., Orditura; E., Matano; R., Bianco; C., Carlomagno; S., Infusino; V., Damiano; E., Simeone; M. R., Diadema; E., Lieto; P., Castellano; Pepe, Stefano; S., De Placido; G., Galizia; F., Ciardiello; G., Catalano; A. R., Bianco
A phase I-II trial of gefitinib (IRESSA) and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck (SCCHN)	1-gen-2005	F., Caponigro; G., Franchin; V., Rav; G., Silvestro; B., Morrica; C., Romano; E., Minatel; Pepe, Stefano
The farnesyltransferase inhibitor R115777 (Zanestra) synergizes with ionizing radiation in inducing cell cycle perturbation and growth inhibition of human epidermoid head and neck cancer cells.	1-gen-2006	Pepe, Stefano; Pacelli, R.; Chianese, M.; Budillon, A.; Abbruzzese, A.; Marra, M.; Sabbatino, F.; Laus, G.; Caraglia, M.
Potentiation of the antitumor acitivity of bortezomib, a proteasome inhibitor, by the combination with EGFR inhibitors in human cancer cell lines.	1-gen-2006	T., Cascone; F., Morgillo; G., Laus; Pepe, Stefano; F., Ciardiello
Synergistic antitumor activity of the combination of the multi-targetes tyrosine kinase inhibitor sorafenib and of EGFR inhibitors in human colon and lung cancer cell lines.	1-gen-2006	E., Martinell; T., Troiani; G., Laus; Pepe, Stefano; F., Ciardiello
Phase I-II study of xelox and bevacizumab plus erlotinib in sequential combination (XELO-TARAV) in first line colorectal cancer: Run in part.	1-gen-2007	G., Tortora; C., Carlomagno; R., Bianco; G., Daniele; Pepe, Stefano; D., Leopardo; R., Marciano; M., De Laurentiis; F., Ciardiello; S., De Placido
Inhibition of poly(ADP-Ribose)plymerase synergizes with the DNA-topoisomerase-1-inhibitor, topoteca, and radiation in human glioblastoma cell lines.	1-gen-2008	Sabbatino, F.; Pacelli, R.; Punzo, G.; Fusciello, C.; Vernieri, C.; Della Vittoria Scarpati, G.; Pepe, Stefano
Cell growth-inhibition and cell cycle perturbations induced by a new synthetic iminoquinone, 5H-pyridophenoxazin-5-one, in human breast carcinoma cell lines.	1-gen-2007	Fusciello, C.; Bolognose, A.; La Vecchia, A.; Ubezio, P.; Sabbatino, F.; Pepe, Stefano
Predictive factors of response to neoadjuvant chemoradiotherapy in rectal cancer patirnts.	1-gen-2008	C., Carlomagno; F., D'Armiento; A., Crispo; G., Della Vittoria Scarpati; M., D'Armiento; M., Marra; L., Cannella; A., De Stefano; M., Colantuoni; S., Alfieri; S., De Placido; Pepe, Stefano
Phase I-II study of sequential combination of XELOX and bevacizumab plus erlotinib (XELOX-TARAV) in first line colorectal patients:Run in phase I part	1-gen-2008	C., Carlomagno; R., Bianco; G., Daniele; R., Marciano; Pepe, Stefano; V., Adamo; F., Ciardiello; S., De Placido; G., Tortora
Autoimmune manifestations in children transplanted for non-autoimmune liver diseases	1-gen-2001	Clemente, Mg; Vajro, Pietro; Musu, Mp; Cicotto, L; Ciccimarra, E; Mandato, Claudia; De Virgiliis, S.
REDUCED LEVELS OF SHP1 PROVIDES AN ADDITIVE SURVIVAL ADVANTAGE TO THE PH(+) CELLS OF CML PATIENTS AND MAY ACCOUNT FOR RESISTANCE TO IMA TREATMENT	1-gen-2008	N., Esposito; I., Colavita; B., Izzo; F., Quarantelli; R. A., Sica; T., Buonomo; V., Roberti; L., Luciano; L. D., Vecchio; A., Peluso; J. V., Melo; D., Russo; G., Martinelli; Martinelli, Rosanna; M., Ruoppolo; F., Pane
Multiple molecular mechanism may account for resistance to imatinib in resistant cell lines	1-gen-2007	N., Esposito; B., Izzo; F., Quarantelli; I., Colavita; T., Buonomo; V., Roberti; S., Soverini; J. V., Melo; G., Martinelli; Martinelli, Rosanna; M., Ruoppolo; B., Rotoli; F., Pane
THE REGULATION OF TRANSCRIPTION DURING THE CELL-CYCLE	1-gen-1993	N., Heintz; F., Labella; Martinelli, Rosanna; N., Segil
H1TF2A - A NOVEL HUMAN TRANSCRIPTION FACTOR INVOLVED IN HISTONE H1 CELL-CYCLE REGULATION	1-gen-1994	Martinelli, Rosanna; N., Heintz
HISTONE GENE-TRANSCRIPTION DURING THE CELL-CYCLE	1-gen-1994	F., Labella; Martinelli, Rosanna; N., Segil; N., Heintz

Prodotti della tipologia (ordinati per Data di deposito in Decrescente ordine): 721 a 740 di 1.217

Legenda icone

file ad accesso aperto
file disponibili sulla rete interna
file disponibili agli utenti autorizzati
file disponibili solo agli amministratori
file sotto embargo
nessun file disponibile

Scopri

Accesso al fulltext

no fulltext1216
open1

UniSa - IRIS Institutional Research Information System